Goldleaf expands grow capacity with new 20-acre property purchase

Grow Opportunity staff
August 07, 2018
By Grow Opportunity staff
Goldleaf Pharm, a subsidiary of FIGR Cannabis Inc., has completed the purchase of a 20-acre property adjacent to its facility in Simcoe, Ont., where it expects to build a greenhouse production facility.

"Goldleaf Pharm is advancing through focused expansion in order to meet the needs of Canadians as we prepare for the legalization of recreational cannabis in Canada," said Larry Huszczo, co-founder of Goldleaf Pharm. "The additional 20-acres of land will give us more production space with the ability to grow our current footprint to more than 700,000 square feet."

"FIGR continues to innovate by focusing on brand and product development," said Volker Lauterbach, president of FIGR Cannabis. "Closing this deal moves us toward our overall strategy and investment goal of reaching one million square feet of production space for our Ontario and Prince Edward Island locations. The Goldleaf Pharm expansion will add well-located production space to support capacity and product development."

Goldleaf Pharm is a late-stage applicant under Health Canada's Access to Cannabis for Medical Purposes Regulations for required licensing to produce and sell medicinal cannabis in Ontario.

FIGR Cannabis Inc. is a holding company that owns majority stakes in two Canadian cannabis producers, Canada's Island Garden in Charlottetown, PEI, and Goldleaf Pharm in Simcoe, Ont.
Grow Opportunity
GET CONNECTED

Stay in-the-know on innovative ways to manage your cannabis business, and grow better. Subscribe to our weekly eNewsletter and be the first to hear what’s new in this fast growing industry.

Add comment


Security code
Refresh

Subscription Centre

 
New Subscription
 
Already a Subscriber
 
Customer Service
 
View Digital Magazine Renew

Most Popular

Latest Events

We are using cookies to give you the best experience on our website. By continuing to use the site, you agree to the use of cookies. To find out more, read our Privacy Policy.